Image

Global Microbiome Modulator Market - Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Microbiome Modulator Market, By Products (Prebiotics, Creams, Probiotics, Drugs, Others), Application (Digestive Health, Immune Health, Oral Health, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2029.

Microbiome Modulator Market

Global Microbiome Modulator Market Analysis and Insights

Microbiomes refer to a group of microorganisms that live on the skin layer, in saliva and the gastrointestinal tract (GIT). Bacteria, archaea and fungi all belong to the category of microbiomes. The microbiomes are helpful in performing certain task that are overall beneficial for human health.            

  • Data Bridge Market Research analyses that the microbiome modulator market will grow at a CAGR of 13.30% during the forecast period of 2022 to 2029. This indicates that the market value was valued at 2.17 billion in 2021 and would stand tall by USD 5.89 billion by 2029.

Microbiome Modulator Market Dynamics

Drivers

  • Lifestyle disorders

Surging incidence rate of chronic health and lifestyle disorders in patients is directly propelling the demand for effective medical treatment. This indicates that the increasing prevalence of hypertension, heart attack, cancer, Alzheimer's disease, asthma, chronic liver disease, diabetes, and osteoporosis will increase the demand for microbiome modulators.      

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the market's growth rate is the rising healthcare expenditure, which helps in improving its infrastructure. Growth and expansion of healthcare industry especially in the developing economies would invite the use and application of new and advanced medial technologies, equipment and drugs. This will directly increase the demand for microbiome modulator treatment.

  • Research and development activities

The growing number of strategic collaboration between public and private market players is inducing growth in the number of research and development activities on a daily basis. These research and development proficiencies are being conducted in novel drugs and medical technologies that will propel the demand for microbiome modulator treatment.

Furthermore, rising initiatives by public and private organizations to spread awareness increasing number of geriatric population and increased demand for prevention medicines with minimum side effects are the factors that will expand the market growth rate. Other factors such as increase in the demand for effective therapies, availability of cost effective drugs and rising adoption rate for early diagnostic procedures will positively impact the market's growth rate.

Opportunities

Rise in the level of personal disposable income and growing awareness in the developing economies pertaining to the availability of treatment options will further create lucrative market growth opportunities. Rising medical tourism globally, growing number of collaborations between market players, increasing involvement of key players in product development and high potential of growth in the untapped market will create enough market growth opportunities.  

Restraints/Challenges Global Microbiome Modulator Market

However, high costs associated with research and development proficiencies and lack of effective treatment which cut down the scope of innovative medication will emerge as one of the biggest restraints for the market. Dearth of awareness and required infrastructural facilities in the underdeveloped and backward economies, stringent government regulations towards approval of biosimilars and unfavourable conditions arising due to COVID-19 outbreak will further derail the market growth rate. Slow rate of approval for drugs and inhibitors, unmet medical needs and increasing cases of patent expiry will also challenge the market growth rate. 

This microbiome modulator market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on microbiome modulator market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

he Human Microbiome Project, conducted in 2012, reported that more than 10,000 microbial species live in the human ecosystem and comprise trillions of cells, making up 1%-3% of the total body mass.

The microbiome modulator market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Microbiome Modulator Market

This pandemic put a dent on the growth rate of the microbiome modulator market. One of the biggest factors responsible for this is thedecreased funding for research and development activities and overall fall in the number of research and development proficiencies. Also, increased focus on essential activities further derailed the market growth rate.    

Recent Development

  • In 2020, Vedanta Biosciences (US) received funding from the Biomedical Advanced Research and Development Authority (BARDA) of USD 7.4 million to advance the clinical development of VE303 for high-risk Clostridioides difficile infection (CDI).

Global Microbiome Modulator Market Scope

The microbiome modulator market is segmented on the basis of products, application, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Products

  • Prebiotics
  • Creams
  • Probiotics
  • Drugs
  • Others

On the basis of products, the microbiome modulator market is segmented into prebiotics, creams, probiotics, drugs, dietary supplements and others.

Application

  • Digestive Health
  • Immune Health
  • Oral Health
  • Others

On the basis of application, microbiome modulator market is segmented into digestive health, immune health, oral health and others.

End-Users

  • Hospitals
  • Specialty Clinics
  • Others

On the basis of end-users, the microbiome modulator market is segmented into hospitals, specialty clinics and others.

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

On the basis of distribution channel, the microbiome modulator market has also been segmented into hospital pharmacy, retail pharmacy and others.

Pipeline Analysis

Microbiome Modulator NM504, developed by MicroBiome Therapeutics LLC, showed promising results in the clinical trial to control blood glucose level and other metabolic parameters in patients with Prediabetes and Type 2 Diabetes.. Quorum Innovations, Merck Sharp & Dohme Corp., Symbiotix Biotherapies, Inc., Ritter Pharmaceuticals and others are the involved in the development of potential drugs for the improvement of treatment of pouchitis treatment.

Microbiome Modulator Market Regional Analysis/Insights

The microbiome modulator market is analysed and market size insights and trends are provided by country, products, application, end-users and distribution channel as referenced above.

The countries covered in the microbiome modulator market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the microbiome modulator market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players, well-developed healthcare infrastructure in this region and increase in the incidence of proctitis and favorable reimbursement policies. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the increase in the awareness about proctitis in developing countries and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Microbiome Modulator Market Share Analysis

The microbiome modulator market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to microbiome modulator market.

Some of the major players operating in the microbiome modulator market are Sanofi, Procter & Gamble, Bayer AG, DSM, DuPont., Yakult Honsha Co., Ltd., BioGaia AB, Probi AB, Chr. Hansen Holding A/S, Ingredion Incorporated, Immuron Ltd, Pharmavite, MICROBIOME THERAPEUTICS, LLC, Otsuka America Pharmaceutical, Inc., Quorum Innovations, Merck Sharp & Dohme Corp., Symbiotix Biotherapies, Inc., and Ritter Pharmaceuticals among others.

Research Methodology : Global Microbiome Modulator Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-microbiome-modulator-market


SKU-
Why Choose Us


Frequently Asked Questions

The Microbiome Modulator Market will be projected to grow at a CAGR of 13.30% during the forecast by 2029.
The Microbiome Modulator Market will be projected at USD 5.89 billion during the forecast by 2029.
On the basis of application, the Microbiome Modulator Market is segmented into Digestive Health, Immune Health, Oral Health, Others.
The major players operating in the Microbiome Modulator Market are Sanofi, Procter & Gamble, Bayer AG, DSM, DuPont., Yakult Honsha Co., Ltd., BioGaia AB, Probi AB, Chr. Hansen Holding A/S, Ingredion Incorporated, Immuron Ltd, Pharmavite, MICROBIOME THERAPEUTICS, LLC, Otsuka America Pharmaceutical, Inc., Quorum Innovations, Merck Sharp & Dohme Corp., Symbiotix Biotherapies, Inc., and Ritter Pharmaceuticals among others.